Updated
Reviewed by Chandani Patel
APAC Pharmacogenomic Testing Market Industry Trends and Forecast to 2034: Segmented by (Test, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$946.2 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $531.9 Mn | — | — |
| 2025 (base) | $591.4 Mn | +$59.6 Mn | — |
| 2026 (forecast) | $657.7 Mn | +$66.2 Mn | +11.2% |
| 2027 (forecast) | $731.3 Mn | +$73.7 Mn | +23.7% |
| 2028 (forecast) | $813.3 Mn | +$81.9 Mn | +37.5% |
| 2029 (forecast) | $904.3 Mn | +$91.1 Mn | +52.9% |
| 2030 (forecast) | $1.01 Bn | +$101.3 Mn | +70% |
| 2031 (forecast) | $1.12 Bn | +$112.6 Mn | +89.1% |
| 2032 (forecast) | $1.24 Bn | +$125.2 Mn | +110.2% |
| 2033 (forecast) | $1.38 Bn | +$139.3 Mn | +133.8% |
| 2034 (forecast) | $1.54 Bn | +$154.9 Mn | +160% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$1.27 Bn
Canada
$238.1 Mn
Japan
$225.2 Mn
China
$224.6 Mn
Germany
$98.1 Mn
France
$92.2 Mn
Brazil
$87.5 Mn
UK
$82.5 Mn
Italy
$72.6 Mn
India
$67.4 Mn
Saudi Arabia
$61.2 Mn
Ecuador
$59.7 Mn
Spain
$52.6 Mn
Mexico
$52.1 Mn
Australia
$36.2 Mn
New Zealand
$33.0 Mn
Russia
$31.8 Mn
South Africa
$20.7 Mn
UAE
$15.7 Mn
Egypt
$8.8 Mn
Philippines
$7.7 Mn
Malaysia
$5.7 Mn
Hong Kong
$5.1 Mn
Thailand
$3.8 Mn
Singapore
$3.7 Mn
Kenya
$2.2 Mn
| Market size, 2025 | $591.4 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $1.54 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 11.2% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Test, application and end user (see all) |
| Key players | Myriad Genetics, Inc., OneOme, Genomind, Thermo Fisher Scientific Inc., RPRD Diagnostics (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Pharmacogenomic testing checks a person's genes to predict how they will respond to medicines, helping choose the right drug and dose.
Key segments of the pharmacogenomic Testing market include test (Multi-Gene Panels and Single-Gene Tests) and application (Psychiatry, Cardiology and Oncology).
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the pharmacogenomic Testing market.
Routine use of genomics in screening, pharmacy and primary care gives the pharmacogenomic Testing market large room to grow.
Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the pharmacogenomic Testing market.
The pharmacogenomic Testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medical devices are regulated by TGA (Australia)[1], NMPA (China)[2], MDACS (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], MDA (Malaysia)[6], Medsafe (WAND) (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9] and Thai FDA (Thailand)[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[11], basic medical insurance (China)[12], the Hospital Authority (Hong Kong)[13], Ayushman Bharat PM-JAY (India)[14], public health insurance (Japan)[15], subsidised public care (Malaysia)[16], Pharmac (New Zealand)[17], PhilHealth (Philippines)[18], MediShield Life (Singapore)[19] and the Universal Coverage Scheme (Thailand)[20].
[1] Therapeutic Goods Administration. Checked 14 Nov 2026.
[2] National Medical Products Administration. Checked 14 Nov 2026.
[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.
[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
[6] Medical Device Authority. Checked 14 Nov 2026.
[7] Medsafe. Checked 14 Nov 2026.
[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.
[9] Health Sciences Authority. Checked 14 Nov 2026.
[10] Thai Food and Drug Administration. Checked 14 Nov 2026.
[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
[12] National Healthcare Security Administration. Checked 14 Nov 2026.
[13] Hospital Authority. Checked 14 Nov 2026.
[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.
[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
[16] Ministry of Health Malaysia. Checked 14 Nov 2026.
[17] Pharmac. Checked 14 Nov 2026.
[18] PhilHealth. Checked 14 Nov 2026.
[19] CPF Board, MediShield Life. Checked 14 Nov 2026.
[20] National Health Security Office. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how pharmacogenomic Testing products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.
What doctors and scientists are doing in Pharmacogenomic Testing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
APAC · 2 shared keywords
APAC · 1 shared keyword
APAC · 1 shared keyword
APAC · 1 shared keyword
APAC · 1 shared keyword
APAC · 1 shared keyword
Pharmaceuticals · APAC
Digital Health · APAC
Healthcare Services · APAC
Healthcare Services · APAC
Digital Health · APAC
Healthcare Services · APAC